Growing Investment EPICS Therapeutics has recently secured €12 million in Series A financing, indicating strong investor confidence and potential for expanded R&D activities, which could lead to increased demand for specialized biotech services and partnerships.

Leadership Transition The company appointed a new CEO, Graeme Fraser PhD, in October 2024, suggesting strategic shifts and potential new initiatives that may require external collaboration, consultancy, or support in drug development and commercialization efforts.

Focus on Oncology EPICS specializes in small molecule drugs targeting RNA epigenetics for cancer treatment, representing an opportunity to offer solutions in precision medicine, targeted therapies, and associated research tools or diagnostics.

Early-Stage Revenue With current revenues under 1 million dollars and active partnerships like the one with Ogeda, there is room for growth in licensing, joint ventures, or collaborative projects to accelerate product pipeline development.

Emerging Biotech Player As a relatively new company founded in 2018 with a focused research niche, EPICS presents opportunities to introduce innovative biotech solutions, specialized laboratory services, or early-stage investment partnerships aligned with its oncology pipeline.